Mira Pharmaceuticals Announces Promising Preclinical Results for SKNY-1, a New Drug Candidate Targeting Obesity and Nicotine Addiction
Mira Pharmaceuticals Inc. has announced the results of a preclinical study involving SKNY-1, an oral drug candidate under a definitive agreement for acquisition. The study, conducted using a zebrafish model, examined the drug's effects on anxiety-related behavior linked to the Cannabinoid 1 receptor (CB1). SKNY-1 demonstrated a reversal of anxiety-induced behavior caused by a CB1 activator, differentiating it from previous CB1-targeting drugs discontinued due to central nervous system side effects. The drug's distinct pharmacological profile includes biased CB1 antagonism, partial CB2 receptor activation, and mild MAO-B inhibition. Mira Pharmaceuticals is preparing for shareholder approval for the acquisition of SKNY Pharmaceuticals, Inc., with plans to initiate Investigational New Drug $(IND.AU)$-enabling studies for SKNY-1 pending approval.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Mira Pharmaceuticals Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001641172-25-018595), on July 10, 2025, and is solely responsible for the information contained therein.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。